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ABSTRACT 
Objectives:  We sought to determine preferences for oral versus long-acting injectable (LAI) 
PrEP among gay and bisexual men (GBM). 
Methods: We surveyed a national U.S. sample of 1,071 GBM about forms of PrEP.  
Results: Overall, 46.0% preferred LAI, 14.3% oral, 21.7% whichever was most effective, 10.1% 
had no preference, and 7.8% would not take PrEP. There were no differences in PrEP 
preferences by race/ethnicity, income, region of residence, or relationship status. Those 
unwilling to take PrEP were significantly older than those who preferred LAI PrEP and those 
who would take either. Those who preferred the most effective form were younger, had less 
education, and reported more recent club drug use. Those who reported condomless anal sex and 
those who thought they were good PrEP candidates were more willing to take PrEP. Long-term 
health and side effects were of the greatest concern for both LAI and oral PrEP.  
Conclusions: The availability of LAI PrEP has the potential to increase uptake among GBM. 
The results of ongoing clinical trials of LAI PrEP will need to demonstrate similar or greater 
efficacy as daily Truvada for uptake to be maximized. 
Key Words: gay and bisexual men; Pre-exposure prophylaxis (PrEP); long-acting 
injectable PrEP; HIV prevention; biomedical strategies 
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INTRODUCTION 
 In the United States, gay and bisexual men (GBM) continue to be disproportionately 
affected by HIV (1, 2). In 2013, GBM represented 68% of all new infections in the U.S., and 
84% of those among men (2); an increase of 12% since 2008 (1). The most promising bio-
medical HIV prevention tool currently available is pre-exposure prophylaxis (PrEP) in the form 
of a once-daily pill named Truvada (emtricitabine (FTC) and tenofovir disproxil fumarate 
(TDF)) (3, 4). In July 2012, the US Food and Drug Administration (USFDA) approved once-
daily Truvada to be used in combination with safer sex practices for HIV-negative individuals at 
high risk for infection (5). Clinical trials have been completed using a variety of samples and 
demonstrate that TDF and FTC/TDF as a once-daily pill reduce the risk of HIV infection by 44-
75% (6-9). Mathematical models using data from these trials estimate the risk reduction to be as 
high as 99% when optimal adherence is met (10). However, within placebo-controlled 
randomized clinical trials conducted to date, optimal once-daily adherence was rarely met by 
participants and non-adherence resulted in the early termination of two trials (11, 12). Another 
dosing regimen being studied is intermittent PrEP (i.e. taking PrEP 2-24 hours before engaging 
in sex and then for two days following) (13). This strategy has been shown to reduce risk by 86% 
in GBM (13). There have been mixed reviews from participants enrolled in intermittent PrEP 
studies as to which form (intermittent vs. once-daily) they prefer (14, 15), as well as concerns 
regarding the ability of GBM to accurately predict sexual activity (16).  
Even with the approval of the USFDA, uptake of once-daily PrEP has been slow, 
particularly among GBM (17, 18), although there is some indication that interest in PrEP is 
increasing (19, 20), at least in urban areas with large populations of GBM. There are many 
possible reasons for the slow uptake including provider initiated barriers (21), costs around 
health care (i.e. quarterly doctor’s visits, health insurance, prescription coverage) (22-24), HIV 
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stigma (25, 26), and the perception among some GBM that, despite engaging in CAS, they are 
not appropriate candidates for PrEP (25). Uptake has been particularly slow among GBM of 
color who may have significant issues with medical mistrust, despite accounting for a 
disproportionate number of new HIV infections (20, 27). One other possible explanation for the 
slow uptake is the necessity for the pill to be taken every day, which was a reoccurring barrier 
mentioned across clinical trials (28, 29). It has been shown, however, that willingness to take 
PrEP and actual PrEP uptake is highest among GBM who report CAS (30). 
To address this daily burden of oral PrEP and its resultant problems with adherence, 
researchers are developing and testing a new long-acting injectable (LAI) form of PrEP, which 
requires a quarterly intramuscular shot (31). This LAI PrEP is made up of cabotegravir and has 
been shown to be effective in the prevention of HIV infection among highly susceptible macaque 
monkeys (32, 33). Currently there are three phase II clinical trials evaluating the safety and 
tolerability of LAI PrEP (NCT02165202; NCT02178800; NCT02076178) in samples at low risk 
of contracting HIV. These trials are expected to be complete in 2016 and 2017 (34, 35).  
If daily dosing is a critical reason for slow uptake and non-adherence of oral PrEP, LAI 
PrEP may provide a potential solution. Past research examining oral PrEP uptake and 
acceptability has predominantly focused on factors including structural access to PrEP (20, 36-
40), demographic characteristics (20, 41-45), substance use (39, 41), sexual risk behaviors (41-
45), and psychological factors(36, 40, 44). However, there is little research on the acceptability 
of injectable PrEP among GBM. As such, we sought to look at similar demographic and 
behavioral variables to examine LAI PrEP acceptability. Using a sample of HIV-negative GBM 
in the U.S., we asked about knowledge and preferences for different forms of PrEP. This 
research is important as it offers insight into preferences for which form of PrEP may be 
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preferred and ultimately may help inform the most acceptable way to protect the broader most at-
risk and affected group of HIV infection in the U.S. 
METHOD 
Participants and Procedures         
The One Thousand Strong panel is a longitudinal study prospectively following a U.S. 
national sample of GBM annually for a period of three years (46). Participants were identified 
via Community Marketing and Insights, Inc. (CMI) panel of over 45,000 LGBT individuals, over 
22,000 of whom are GBM throughout the United States. CMI draws panelists from over 200 
sources ranging from LGBT events to social media and email broadcasts distributed by LGBT 
organizations, and includes non-gay identified venues/mediums such to maintain a robust and 
diverse panel of participants from across the United States. CMI targeted individuals based on 
pre-specified characteristics and invited them to participate in our study. Our goal was to recruit 
a sample representing the diversity and distribution of GBM at the U.S. population level. In so 
doing, we used data from the U.S. Census with regard to same sex households, and racial and 
ethnic composition to populate our recruitment parameters. CMI identified participants from 
their panel, screened them for eligibility, and shared their responses and contact information with 
the research team; we then independently enrolled participants for the longitudinal assessment.  
Eligible participants had to reside in the U.S., be at least 18 years of age, be biologically 
male, identify as male, identify as gay or bisexual, report having sex with a man in the past year, 
able to complete Internet-based assessments in English, have access to a device that was capable 
of taking a digital photo, have an address to receive mail that was not a P.O. Box, report 
residential stability (i.e., have not moved more than twice in the past 6 months), and complete at-
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home, self-administered rapid HIV antibody testing (those testing positive at baseline were not 
included in the panel) as well as urethral and rectal chlamydia/gonorrhea. 
Participants were enrolled over a period of 6 months (April 2014-October 2014). In total, 
1,071 participants joined the study. Approximately 6 months after their baseline assessment, 
participants were sent an email with a link to verify their contact information had not changed. 
They were also invited to complete a brief (~10 minute) survey about PrEP. As an incentive, 
participants were offered entry into a raffle for one of 50 Amazon gift cards for $20. In total 950 
(88.7%) participants completed this survey; however, we excluded data from two men who 
indicated they had been diagnosed with HIV since baseline. Thus the analytic sample for the 
current study is 948. The [BLINDED] Institutional Review Board approved study procedures.  
Baseline Measures 
 During the online baseline CASI, participants indicated their demographic characteristics 
(e.g., race or ethnicity, education, income, zip code, and relationship status), as well as whether 
or not they had used drugs (i.e., cocaine/crack, crystal methamphetamine, ecstasy/MDMA, GHB, 
or heroin) in the previous three months and if they had engaged in any condomless anal sex 
(CAS) with casual male partners in the previous three months 
6-Month PrEP Measures 
 During the optional follow-up survey, participants were presented with the following 
description of PrEP: 
PrEP (pre-exposure prophylaxis) is a new biochemical strategy to prevent HIV infection. 
PrEP involves HIV-negative guys taking anti-HIV medications (for example, Truvada) 
once a day, every day to reduce the likelihood of HIV infection if they were exposed to 
the virus. Clinical trials of PrEP indicated that it reduced the likelihood of HIV infection 
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when used in combination with other preventative methods, such as condoms. Please note 
that PrEP is not the same as taking HIV medications for a brief period of time (i.e., 28 
days) after a high risk exposure to HIV through encounters such as being stuck by a 
contaminated needle or having unprotected intercourse. PrEP is intended for regular, 
long-term use. 
Following this, they responded to a series of general PrEP questions. To assess perceived 
appropriateness of PrEP for themselves, participants were asked, “Do you believe that you are 
currently an appropriate candidate for PrEP?” with responses ranging from “Yes, I am definitely 
an appropriate candidate” to “No, I am definitely not an appropriate candidate.” To assess 
willingness to take oral PrEP, participants were asked, “Suppose that PrEP is at least 90% 
effective in preventing HIV when taken daily. How likely would you be to take PrEP if it were 
available for free?” with responses ranging from “I would definitely take it” to “I would 
definitely not take it.” Participants were next asked about how concerned they were about a 
series of potential barriers to taking PrEP with responses ranging from 1 (not at all concerned) to 
4 (very concerned) (40). 
 Following these general PrEP questions, participants received the following description 
of LAI PrEP: 
Scientists are also working to make a different kind of PrEP that would not require taking 
a pill every day. Instead, it would involve getting an injection or shot in the muscle of the 
butt every month or perhaps only every 3 months.  Based on past experiments, scientists 
believe that this new drug can work similarly to daily oral PrEP to prevent HIV, but 
conclusive results from human trials have not yet been obtained. We are interested in 
knowing some of your opinions about this second form of PrEP, which we will call 
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“long-acting injectable PrEP” due to the fact that the injections would last from one to 
three months. 
Participants were asked how familiar they were with LAI PrEP with responses ranging from 
“I’ve never heard of it before today” to “I know a lot about it.” Participants rated their 
willingness to take LAI PrEP in the same way they were asked about oral PrEP—specifically, 
“Suppose that long-acting injectable PrEP is at least 90% effective in preventing HIV when 
injected once every month. How likely would you be to take this long-acting injectable PrEP if it 
were available for free?” with response options ranging from “I would definitely take it” to “I 
would definitely not take it.” Participants were also asked, “In general, are you the type of person 
who would rather…” with response options of “Take a pill every single day,” “Take a pill 2-3 
times per week,” and “Receive an injection every 3 months.” Participants were asked about 
barriers to LAI PrEP with a nearly identical measure as was used for oral PrEP with two 
additional items regarding the lasting effects “wearing off” and a fear of needles. 
 Finally, to assess preferences for oral versus LAI PrEP, participants were asked, “Given 
the choice between either form of LAI PrEP and daily oral PrEP, would you prefer to take…” 
with responses options of “LAI PrEP,” “daily oral PrEP,” “either LAI or daily PrEP – no 
preference,” “either LAI or daily PrEP – whichever is most effective,” and “neither – I would not 
take PrEP.” 
Statistical Analyses 
 We examined basic descriptive statistics for variables of interest, including demographic, 
behavioral, and PrEP-related factors, and then examined the association between these factors 
and the five-category variable for PrEP preferences using chi-square statistics. In cases of 
significant omnibus chi-square statistics, we utilized standardized residuals greater than the 
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absolute value of 2 to report on the areas of greatest difference in the table. We also utilized an 
analysis of variance (ANOVA) to compare mean age across the four categories and utilized least 
squared difference (LSD) post-hoc tests to examine pairwise comparisons. Finally, we utilized 
paired-samples t-tests to compare responses to the barriers items for oral and LAI PrEP to 
examine within-person differences. 
RESULTS 
 A majority of the sample was White, with slightly more than one-quarter being men of 
color (Table 1). There was a diversity of representation with regard to education, income, 
geographic region of residence, and relationship status. The average age in the sample was 40 
and ranged from 18 to 79. Less than 10% of the sample reported having used club drugs within 
the three months prior to the baseline survey. We found that 92.8% (n = 880) had never been 
prescribed PrEP, 5.9% (n = 56) were currently prescribed PrEP, and 1.3% (n = 12) had 
previously been prescribed PrEP. With regard to preferences for types of PrEP, nearly half 
(46.0%) of the sample expressed a preference for LAI PrEP, 14.3% preferred oral PrEP, 21.7% 
preferred whichever turns out to be most effective, 10.1% had no preference between the two 
forms of PrEP, and 7.8% said they would not take either form of PrEP. Overall, only 10.1% (n = 
96) reported any familiarity with LAI PrEP, with only 30 men reporting they knew a fair amount 
or a lot about it. 
 Table 1 also reports on the demographic associations with PrEP preferences. As can be 
seen, there were no associations for race/ethnicity, annual income, geographic region of 
residence, or relationship status. In contrast, there were significant associations with educational 
attainment, recent club drug use, and age. Standardized residuals suggested that a greater number 
of those with a high school education or less expressed a preference for the most effective form 
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of PrEP. Significantly more club drug users preferred LAI or whichever form was most effective. 
Post-hoc tests indicated that those who would not take PrEP at all were significantly older (p < 
0.05) than those who preferred LAI PrEP and those who would take the most effective form, and 
those who would take the most effective form were also significantly younger than those who 
preferred oral PrEP. 
 We next examined PrEP-specific factors that might differentiate PrEP preferences and 
found several significant associations (Table 2). Engaging in CAS with casual male partners in 
the 3 months prior to the baseline appointment was associated with PrEP preferences, with 
standardized residuals suggesting that a lower proportion of those who engaged in CAS indicated 
they would not take PrEP at all. Perceptions of being an appropriate candidate for PrEP were 
associated with preferences, with more men who believed they were appropriate candidates 
expressing willingness to take whichever form is most effective and fewer reporting they would 
not take PrEP at all.  Whether or not participants were familiar with LAI PrEP prior to taking the 
survey was unassociated with PrEP preferences. Willingness to take oral PrEP was associated 
with PrEP preferences, with more unwilling men reporting a preference for neither form of PrEP 
and fewer of them reporting a preference for the most effective form of PrEP; similarly, more of 
those currently prescribed PrEP expressed willingness to take the most effective form of PrEP. 
Among those who reported willingness to take LAI PrEP, a greater number reported preferences 
for LAI PrEP and a lower number reported they preferred oral PrEP or would not take PrEP at 
all. Similarly, among those who saw themselves as the type who would typically prefer to take 
an injection to taking a pill, a greater number preferred LAI PrEP, with the opposite being true 
among those who reported they were the type to prefer taking a pill every day or taking a pill a 
few days a week (i.e., preferences for oral PrEP were highest). 
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 The comparisons of barriers to PrEP uptake and maintenance for both oral and LAI PrEP 
are reported in Table 3. The long-term health effects and concerns about side effects were of the 
greatest concern and there were no differences in level of concern regarding the effects for oral 
versus LAI PrEP. Participants reported slightly less concern about the possibility for incomplete 
protection from PrEP, though this also did not differ by type of PrEP. Finally, with regard to 
having to return for medical visits every three months, participants reported this as significantly 
less of a burden for LAI PrEP than oral PrEP. We also assessed one barrier specific to oral PrEP 
and two specific to LAI PrEP and found that participants generally rated them lower than the 
more general health concerns, with a fear of needles being the least concerning. 
DISCUSSION 
 As one might expect given that research on LAI PrEP is still within Phase II trials, the 
vast majority of men in our national US sample (90%) had never heard of LAI PrEP prior to our 
survey. Once LAI PrEP was described, 46% of men indicated a preference for LAI PrEP, 
although nearly 22% said they would prefer whichever form of PrEP was most effective, 
suggesting that LAI PrEP will have to demonstrate that it is at least as effective as daily oral 
PrEP in order for uptake to be greater than that of oral PrEP. Even among those currently 
prescribed daily oral PrEP (6% of the sample), nearly one-third expressed a preference for LAI 
PrEP and only 16% indicated a preference for oral PrEP, suggesting that a number of GBM may 
want to change their PrEP modality should a LAI form become available. Further, those 
currently prescribed PrEP were more likely to be interested in the most effective form, 
suggesting that the level of protection against HIV is one of the most important factors in 
deciding which form of PrEP to use, particularly for these early adopters of oral PrEP.  
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We did not find any significant differences in PrEP preferences among demographic 
variables such as race/ethnicity, income, geographic region, or relationship status. However, age 
was significantly associated with PrEP preferences, with those disinterested in both forms of 
PrEP being oldest, on average. Data suggest that nearly 50% of all Americans living with HIV 
are over the age of 50 (47, 48), and with increasing numbers of older GBM contracting HIV, this 
is a group for whom PrEP uptake may be very beneficial; however, efforts to promote uptake 
among older GBM at risk of infection may prove particularly challenging. Younger and less 
educated GBM were interested in the most effective form of PrEP, and substance users were 
interested either in the most effective form or LAI, suggesting that some subgroups of GBM may 
be most receptive to targeted messaging around PrEP options should LAI become available. 
 The best candidates for PrEP are GBM who report a history of inconsistent or no condom 
use (4), and our results further support the notion that willingness to take PrEP is highest among 
these men who are at the greatest risk of infection (30). Men in our sample who reported CAS 
expressed a preference for each form of PrEP rather than neither form of PrEP, but did not 
express preferences among the types of PrEP. Overall, willingness to take LAI PrEP was 
associated with a preference for LAI PrEP over oral. Nearly 64% of GBM viewed themselves as 
the type of person who would rather have an injection every three months (compared to taking a 
pill daily or 2-3 times a week), and, not surprisingly, these individuals were more likely to 
express a preference for LAI PrEP. Interestingly, only 14% of participants viewed themselves as 
the type of person who would prefer to take a pill only 2-3 times a week rather than daily pill-
taking or injection, suggesting that there may be a limited population for whom intermittent oral 
dosing of PrEP would be the preferred method One recent study found that implementing 
intermittent PrEP dosing schedules that are centered around sexual events (i.e., event-contingent 
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dosing) may be problematic among highly sexually active GBM—who are prime targets for 
PrEP—due to their inability to accurately predict when they will have sex.(16) The findings of 
these two studies suggest that research into LAI PrEP may warrant higher priority than 
developing new dosing schedules for oral PrEP for GBM. 
 Regardless of preferences for any particular form of PrEP, these data suggest that the 
biggest concerns regarding both forms of PrEP are the same—men were primarily concerned 
about their unwanted effects on health. In comparison, the concerns unique to LAI PrEP (i.e., 
those about needles and the effects “wearing off” if one does not return for their next visit on 
time) were rated with less concern, suggesting men have more general PrEP-related concerns 
that are primarily unrelated to the mode of administration. One other possible explanation for the 
slow uptake of oral PrEP is the necessity for the pill to be taken every day, which was a 
reoccurring barrier mentioned across clinical trials (28, 29). However, our findings demonstrate 
that this is relatively low on the list of concerns participants have about PrEP, with general health 
effects being more concerning. 
Limitations 
 The current study has some important limitations. We asked about both forms of PrEP 
with the assumption that the medication would be available for free, thus removing cost as a 
potential barrier. With an increasing number of states increasing the availability of funding for 
PrEP, it may be feasible to obtain LAI PrEP for low or no cost, though this is not a guarantee and 
thus the acceptability of both forms of PrEP should be considered hypothetical. We also had 
participants assume LAI PrEP was as effective as daily oral PrEP, which has yet to be 
demonstrated within the clinical literature. Other characteristics of the description of LAI PrEP 
limit its correspondence with current protocols being tested, including the quantity of the dose 
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(two large shots, one in each buttocks) and the probable need to take the medication orally for a 
period of time prior to receiving LAI PrEP to rule out any adverse reactions. Finally, although 
our sample is a national one from across the US, and represents an important general population 
among whom to test the acceptability of this novel form of PrEP, a large majority identified as 
White, and with high levels of education and income. More importantly, the sample was not 
selected for risk and a proportion of them may not make ideal candidates for any form of PrEP. 
Future studies should examine willingness and preference for LAI and other forms of PrEP 
among more diverse samples, including those who report CAS, as these GBM are the best 
candidates for PrEP. 
Conclusions 
Although awareness of LAI PrEP among this national sample of GBM remains low at 
this early stage of investigation, the present results hint at a potentially promising future for this 
mode of administration. Among GBM who are willing to take PrEP, the largest number of men 
were interested in LAI PrEP, followed by whichever form is most effective, with fewer 
expressing a preference for daily oral PrEP. These findings suggest that convenience (i.e., not 
taking a pill every day) and effectiveness may be two primary underlying motivators of PrEP 
preferences. Moreover, men expressed similar concerns about both oral and LAI PrEP that were 
centered around their potential negative health effects. Based on these results, we suggest that 
two of the central foci of future clinical trials of LAI PrEP should be to document the 
comparative effectiveness of LAI versus oral PrEP and to compare the negative health effects of 
each. Taken together, these findings indicate that adding LAI PrEP to the biomedical options for 
HIV prevention has the potential to increase uptake among GBM, although clear comparisons of 
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the two modes of administration will be important in assisting with decision making if and when 
the two forms are offered simultaneously.   
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Table 1 
Demographic characteristics and associations with preferences for PrEP type 
 
Full Sample 
(N = 948) 
 
Preferences for Type of PrEP 
 
  
LAI 
(n = 436) 
 
Oral 
(n = 136) 
 
Either - 
Whichever 
is Most 
Effective 
(n = 206) 
 
Either - No 
Preference 
(n = 96) 
 
Neither - 
Would not 
take PrEP 
(n = 74) 
 
  n %   n %   n %   n %   n %   n % χ2(df), p-value 
Race/ethnicity 
                 
13.20 (12), 0.35 
Black 68 7.2 
 
25 5.7 
 
12 8.8 
 
13 6.3 
 
9 9.4 
 
9 12.2 
 Latino 119 12.6 
 
61 14.0 
 
15 11.1 
 
22 10.7 
 
15 15.6 
 
6 8.0 
 White 683 72.0 
 
308 70.6 
 
103 76.3 
 
155 75.2 
 
64 66.7 
 
53 70.7 
 Other/multiracial 78 8.2 
 
42 9.6 
 
6 4.4 
 
16 7.8 
 
8 8.3 
 
6 8.0 
 Education 
                 
22.81 (12), 0.03 
High school degree or less 66 7.0 
 
20 4.6 
 
11 8.1 
 
18 8.7 
 
14 14.6 
 
3 4.1 
 Some college or Associate's degree 348 36.7 
 
163 37.4 
 
53 39.3 
 
69 33.5 
 
35 36.5 
 
28 37.3 
 Bachelor's degree 274 28.9 
 
121 27.8 
 
35 25.9 
 
73 35.4 
 
22 22.9 
 
23 30.7 
 Graduate school or degree 260 27.4 
 
132 30.3 
 
37 27.4 
 
46 22.3 
 
25 26.0 
 
20 26.7 
 Income 
                 
12.82 (12), 0.38 
Less than $20k per year 190 20.0 
 
75 17.2 
 
31 22.8 
 
45 21.8 
 
25 26.0 
 
14 18.9 
 $20k to $49k per year 314 33.1 
 
148 33.9 
 
46 34.1 
 
67 32.5 
 
34 35.4 
 
19 25.3 
 $50k to $74k per year 183 19.3 
 
80 18.3 
 
29 21.5 
 
43 20.9 
 
14 14.6 
 
17 22.7 
 $75k or more per year 261 27.5 
 
133 30.5 
 
30 22.2 
 
51 24.8 
 
23 24.0 
 
24 32.0 
 Geographic Region 
                 
12.69 (12), 0.39 
Northeast 186 19.6 
 
81 18.6 
 
26 19.3 
 
42 20.4 
 
20 20.8 
 
17 22.7 
 South 329 34.7 
 
159 36.5 
 
39 28.7 
 
82 39.8 
 
27 28.1 
 
22 29.7 
 Midwest 165 17.4 
 
75 17.2 
 
23 17.0 
 
33 16.0 
 
17 17.7 
 
17 22.7 
 West 267 28.2 
 
120 27.5 
 
48 35.6 
 
49 23.8 
 
32 33.3 
 
18 24.0 
 U.S. Possession
a
 1 0.1 
 
-- -- 
 
-- -- 
 
-- -- 
 
-- -- 
 
-- -- 
 Relationship Status 
                 
7.59 (4), 0.11 
Single 489 51.6 
 
228 52.3 
 
71 52.2 
 
112 54.4 
 
51 53.1 
 
27 36.5 
 Partnered 459 48.4 
 
208 47.7 
 
65 48.1 
 
94 45.6 
 
45 46.9 
 
47 62.7 
 Any Recent Club Drug Use 
                 
9.63 (4), 0.05 
Yes 81 8.5 
 
44 10.1 
 
10 7.4 
 
22 10.7 
 
3 3.1 
 
2 2.7 
 No 867 91.5 
 
392 89.9 
 
126 92.6 
 
184 89.3 
 
93 96.9 
 
72 97.3 
 
                   
  M SD   M SD   M SD   M SD   M SD   M SD 
F(4, 943), p-
value 
23 
Age (Mdn = 39.0) 40.3 13.8   39.9 13.7   41.7 14.7   38.5 13.4   41.5 13.8   44.18 12.8 2.96, 0.02 
Note. 
a
Not included in calculation of chi-square. 
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Table 2 
PrEP-specific characteristics and associations with preferences for PrEP type 
    
Preferences for Type of PrEP 
 
 
Full 
Sample 
(N = 948) 
 
LAI 
(n = 436) 
 
Oral 
(n = 136) 
 
Either - 
Whichever 
is Most 
Effective 
(n = 206) 
 
Either - 
No 
Preference 
(n = 96) 
 
Neither - 
Would not 
take PrEP 
(n = 74) 
 
  n %   n %   n %   n %   n %   n % χ2(df), p-value 
Any CAS with casual male partners 
                 
15.84 (4), 0.003 
Yes 325 34.3 
 
155 35.6 
 
49 36.3 
 
78 37.9 
 
33 34.4 
 
10 13.5 
 No 623 65.7 
 
281 64.4 
 
87 64.0 
 
128 62.1 
 
63 65.6 
 
64 86.5 
 Perceived appropriateness of PrEP 
                 
79.24 (8), < 0.001 
Yes, I'm an appropriate candidate 390 41.1 
 
175 40.1 
 
50 36.8 
 
112 54.4 
 
48 50.0 
 
5 6.8 
 I'm not sure who is an appropriate candidate 236 24.9 
 
117 26.8 
 
41 30.1 
 
42 20.4 
 
22 22.9 
 
14 18.9 
 No, I'm not an appropriate candidate 322 34.0 
 
144 33.0 
 
45 33.1 
 
52 25.2 
 
26 27.1 
 
55 74.3 
 Familiar with LAI PrEP 
                 
4.54 (4), 0.34 
No 852 89.9 
 
392 89.9 
 
126 92.6 
 
178 86.4 
 
88 91.7 
 
68 91.9 
 Yes (a little to a lot) 96 10.1 
 
44 10.1 
 
10 7.4 
 
28 13.6 
 
8 8.3 
 
6 8.1 
 Willingness to take daily oral PrEP 
                 
117.40 (8), < 0.001 
Currently prescribed 56 5.9 
 
18 4.1 
 
9 6.6 
 
24 11.7 
 
5 5.2 
 
0 0.0 
 Willing 512 54.0 
 
248 56.9 
 
78 57.4 
 
120 58.3 
 
62 64.6 
 
4 5.4 
 Unwilling 380 40.1 
 
170 39.0 
 
49 36.0 
 
62 30.1 
 
29 30.2 
 
70 94.6 
 Willingness to take 3-month LAI PrEP 
                 
155.76 (4), < 0.001 
Willing 507 53.5 
 
295 67.7 
 
39 28.7 
 
117 56.8 
 
56 58.3 
 
0 0.0 
 Unwilling 441 46.5 
 
141 32.3 
 
97 71.3 
 
89 43.2 
 
40 41.7 
 
74 100.0 
 Type of person who would prefer to… 
                 
427.18 (8), < 0.001 
Take a pill every day 210 22.2 
 
12 2.8 
 
87 64.0 
 
57 27.7 
 
33 34.4 
 
21 28.4 
 Take a pill 2-3 times per week 132 13.9 
 
14 3.2 
 
46 33.8 
 
38 18.4 
 
18 18.8 
 
16 21.6 
 Receive an injection every 3 months 606 63.9 
 
410 94.0 
 
3 2.2 
 
111 53.9 
 
45 46.9 
 
37 50.0 
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Table 3 
Within-person comparisons of barriers to uptake for oral versus long-acting injectable PrEP 
 
Oral 
 
Injectable 
  Barriers to uptake M SD   M SD   t(947), p-value 
Long-term health effects 3.10 0.92 
 
3.11 0.92 
 
-0.96, 0.34 
Potential side effects 3.11 0.89 
 
3.10 0.88 
 
0.73, 0.47 
Possibility of incomplete protection 2.89 0.95 
 
2.89 0.93 
 
0.19, 0.85 
Returning for medical check-ups every 3 months 2.15 1.05 
 
2.04 1.01 
 
4.29, < 0.001 
Having to remember to take PrEP every day 1.85 0.97 
 
-- -- 
 
N/A 
Possibility it might "wear off" if I don’t return on time -- -- 
 
2.66 0.98 
 
N/A 
Fear or dislike of needles -- --   1.71 1.01   N/A 
